Onzeald (etirinotecan pegol)
- Region
- 🇪🇺 EU
- Active substance
- etirinotecan pegol
- Company
- Nektar Therapeutics UK Limited
- Status
- Refused
- Therapeutic area
- Breast Neoplasms
- CHMP opinion
- Thu 09 Nov 2017
- Application
- EMEA/H/C/003874
- ATC
- L01
- Official record
- www.ema.europa.eu
Indication
Treatment of breast cancer with brain metastases
Regulatory milestones
No milestones recorded in the last year.
Follow Onzeald
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.